Patents Assigned to Illumigen Biosciences, Inc.
-
Publication number: 20110071073Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: November 2, 2006Publication date: March 24, 2011Applicant: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer
-
Publication number: 20100256348Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: March 30, 2010Publication date: October 7, 2010Applicant: ILLUMIGEN BIOSCIENCES, INC.Inventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20100172833Abstract: Methods for the diagnosis of hepatocellular carcinoma (HCC) are set forth. Improved assay methods and scanning methods are included that employ non-cell-associated and cell-associated HCC related proteins. Such methods are based upon the discovery of genes that were up-regulated in diseased versus normal tissue as well as in HCC tissue when compared to the tissue of patients with other ailments.Type: ApplicationFiled: August 7, 2009Publication date: July 8, 2010Applicants: ILLUMIGEN BIOSCIENCES, INC., UNIVERSITY OF WASHINGTONInventors: Michael Katze, Roger Bumgarner, Mariya Smit, Gary Rosenberg
-
Patent number: 7732177Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: GrantFiled: November 17, 2006Date of Patent: June 8, 2010Assignee: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20090291074Abstract: Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.Type: ApplicationFiled: October 9, 2008Publication date: November 26, 2009Applicant: Illumigen Biosciences Inc.Inventors: Shawn P. IADONATO, Charles L. Magness, P. Campion Fellin, Christina A. Scherer, Tory Hagen, Amy Olson
-
Patent number: 7588902Abstract: Methods for the diagnosis of hepatocellular carcinoma (HCC) are set forth. Improved assay methods and scanning methods are included that employ non-cell-associated and cell-associated HCC related proteins. Such methods are based upon the discovery of genes that were up-regulated in diseased versus normal tissue as well as in HCC tissue when compared to the tissue of patients with other ailments.Type: GrantFiled: July 3, 2003Date of Patent: September 15, 2009Assignee: Illumigen Biosciences, Inc.Inventors: Michael Katze, Roger Bumgarner, Mariya Smit, Gary Rosenberg
-
Patent number: 7569348Abstract: This invention provides methods for identifying mutations and methylation patterns in diploid DNA sequence signal data. In particular, the invention provides methods for (1) obtaining two parental allele sequences from diploid DNA sequence signal data, (2) identifying the mutation and haplotype patterns in the two parental allele sequences, (3) assigning likelihood scores for the mutations thus identified, and (4) identifying patterns of methylation.Type: GrantFiled: February 3, 2006Date of Patent: August 4, 2009Assignee: Illumigen Biosciences Inc.Inventors: Charles L. Magness, Dake Sun
-
Publication number: 20090186028Abstract: A method for detecting a mutation related to the gene encoding LDLR. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human LDLR, including antisense oligonucleotides, methods, and compositions specific for human LDLR, are also provided.Type: ApplicationFiled: June 27, 2005Publication date: July 23, 2009Applicant: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Christina A. Scherer
-
Publication number: 20090123472Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: April 2, 2008Publication date: May 14, 2009Applicant: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer
-
Publication number: 20080152650Abstract: Particular aspects of the present invention provide methods and compositions for the targeting and/or treating hepatocellular carcinoma (HCC) cells to affect cancer cell growth or viability. Exemplary methods and compositions relate to cell-associated HCC proteins (e.g., SEQ ID NOS:1-8, corresponding to PGMRCI (prostaglandin receptor membrane component 1), SEMA5A (semaphorin 5A), SLC2A2 (solute carrier family member), ABCC2 (ATP-binding cassette subfamily C member 2) and HAL (histidine ammonia lyase)), and are based, at least in part, upon the discovery that specific target genes and/or gene products are up or down-regulated in diseased tissue relative to normal tissue or in tissue of patients having other ailments. Inventive compositions comprise, for example, antibodies, antisense and siRNA agents.Type: ApplicationFiled: April 27, 2005Publication date: June 26, 2008Applicant: ILLUMIGEN BIOSCIENCES, INC.Inventors: Gary Rosenberg, Shawn P. Iadonato
-
Publication number: 20080124311Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: November 17, 2006Publication date: May 29, 2008Applicant: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Mark Branum, Maralee McVean, Christina Scherer
-
Publication number: 20080038753Abstract: The invention describes methods for manufacturing oligoadenylate synthetase (OAS) proteins for use as active pharmaceutical ingredients in pharmaceutical compositions. A manufacturing method is described that produces large quantities of concentrated, highly active OAS protein for use in pharmaceutical compositions for the treatment of a variety of diseases including viral infection. Methods for monitoring and validating the manufacturing process are also described.Type: ApplicationFiled: July 31, 2007Publication date: February 14, 2008Applicant: ILLUMIGEN BIOSCIENCES, INC.Inventors: Mark BRANUM, Maralee McVEAN, Just JUSTESEN, Eric TARCHA
-
Publication number: 20070154467Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: November 2, 2006Publication date: July 5, 2007Applicant: Illumigen Biosciences, Inc.Inventors: Shawn Iadonato, Charles Magness, Gary Rosenberg, Christina Scherer, Thierry Guillaudeux
-
Publication number: 20070111231Abstract: Compositions and methods are provided for detecting a mutation in a human oligoadenylate synthetase gene, particularly OAS2 or OAS3, wherein the mutation confers resistance to flavivirus infection, including infection by hepatitis C virus, and the mutation relates to other disease states including prostate cancer and diabetes, and uses of the encoded proteins and antibodies thereto.Type: ApplicationFiled: August 23, 2006Publication date: May 17, 2007Applicant: Illumigen Biosciences, Inc.Inventors: Charles Magness, Shawn Iadonato, Christina Scherer, Phillip Fellin, Kathryn Steiger
-
Publication number: 20060154290Abstract: This invention provides methods for identifying mutations and methylation patterns in diploid DNA sequence signal data. In particular, the invention provides methods for (1) obtaining two parental allele sequences from diploid DNA sequence signal data, (2) identifying the mutation and haplotype patterns in the two parental allele sequences, (3) assigning likelihood scores for the mutations thus identified, and (4) identifying patterns of methylation.Type: ApplicationFiled: February 3, 2006Publication date: July 13, 2006Applicant: Illumigen Biosciences, Inc.Inventors: Charles Magness, Dake Sun
-
Patent number: 7041455Abstract: This invention provides methods for identifying mutations and methylation patterns in diploid DNA sequence signal data. In particular, the invention provides methods for (1) obtaining two parental allele sequences from diploid DNA sequence signal data, (2) identifying the mutation and haplotype patterns in the two parental allele sequences, (3) assigning likelihood scores for the mutations thus identified, and (4) identifying patterns of methylation.Type: GrantFiled: March 7, 2003Date of Patent: May 9, 2006Assignee: Illumigen Biosciences, Inc.Inventors: Charles Lee Magness, Dake Sun
-
Publication number: 20050191649Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: October 22, 2004Publication date: September 1, 2005Applicant: Illumigen Biosciences, Inc.Inventors: Shawn Iadonato, Charles Magness, Gary Rosenberg, Christina Scherer
-
Publication number: 20040175702Abstract: This invention provides methods for identifying mutations and methylation patterns in diploid DNA sequence signal data. In particular, the invention provides methods for (1) obtaining two parental allele sequences from diploid DNA sequence signal data, (2) identifying the mutation and haplotype patterns in the two parental allele sequences, (3) assigning likelihood scores for the mutations thus identified, and (4) identifying patterns of methylation.Type: ApplicationFiled: March 7, 2003Publication date: September 9, 2004Applicant: Illumigen Biosciences, Inc.Inventors: Charles Lee Magness, Dake Sun